Development Board Member Biographies
Jeffery Coombs ’81, Chairperson
Jeff Coombs has been President and CEO of A&B Lumber Company since 1996, a retail lumberyard with locations in Pembroke and Moultonboro, N.H. A&B also designs and provides materials for agricultural buildings of all types and is well known for New England style practical designs.
He is the Owner and Manager of Ossipee Mountain Land Company, a company he co-founded with former ITT Chairman Harold S. Geneen in 1985. Specializing in kiln dried packaged firewood for the New England market, producing over 5,000 cords annually. OMLC is a forest product and management company located in Tamworth, N.H.
As a licensed forester he has been Forest Manager for Chocorua Forestlands, LLC, since 1984. Chocorua is a privately held company that owns 15,000 acres of multiple use sustainably managed forest land in Central New Hampshire.
Jeff holds an AAS in Forest Technology from the University of New Hampshire, a BS in Forest Resource Administration from Central Washington University, and a Masters in Business Administration from Plymouth State University.
He was President of the New Hampshire Timberland Owners Association from 2000-2001 and a board member from 1994– 2002. Jeff has served as a board member of the UNH Thompson School Forestry Curriculum Advisory Board since 1987, the UNH Thompson School Leadership Council since 2003 and Project Learning Tree from 1994-1996. He is a member of The Society of American Foresters, The Forest Guild, The Forest History Society as well as many lumbermens’ and builders’ associations.
Christine Carberry ’82
Christine Carberry is Vice President, Program and Alliance Management with EnVivo Pharmaceuticals in Watertown, MA. Prior to joining EnVivo in 2012, Christine was Vice President, Program and Alliance Management at Biogen Idec for several years, advancing the company from a biotechnology pioneer to a Fortune 500 company with more than $4 billion in revenue. Her role spanned global co-development/co-commercialization alliances, strategic planning, R&D operations and program management. Christine previously held many positions in technical operations, including the start-up of Biogen’s first European manufacturing facility. Christine is a Certified Strategic Alliance Professional (CSAP). She holds an M.S. in innovation and technology management from Boston University, Certificates in Management and Biotechnology Strategy from Harvard University, and a B.S. in biochemistry from the University of New Hampshire.
Henry L. Huntington '80
Henry is president of Pleasant View Gardens, Inc., a 13-acre wholesale greenhouse operation specializing in ornamental floriculture with locations in Loudon and Pembroke as well as Costa Rica. Founded by his parents, Pleasant View Gardens is now owned by Henry and his brother, Jeffrey, who are also partners in Proven Winners, LLC, a plant brand marketing company; Plant 21, LLC, a plant breeding company; and Ticoplant of Costa Rica, an offshore unrooted cutting production company.
Henry holds an Associates Degree from the Thompson School of Applied Science at the University of New Hampshire. He is a recent director of the Ohio Florists Association, co-chair of the New Hampshire Ornamental Horticulture Endowment, member of the Leadership Advisory Board for the Thompson School of Applied Science, past president of Bedding Plants International, and a fifteen-year member of the Planning Board for the Town of Loudon.
John Rossi '69
Dr. John Rossi received his Bachelor of Science in Biology from the University of New Hampshire and his doctorate in Microbial Genetics from the University of Connecticut in Storrs. For postdoctoral training, John attended Brown University Medical School in Providence, Rhode Island, where he trained under Dr. Arthur Landy, studying the genomic structure, organization, and expression of two gene clusters encoding tRNA-tyrosine in E. coli.
In 1980, John moved to the Department of Molecular Genetics at the City of Hope in Duarte, California. John’s laboratory began to develop and test the idea of utilizing catalytic RNAs – or ribozymes – to inhibit HIV infection. This research program has led to two clinical trials in HIV infected individuals and a first-of-its-kind clinical trial using a triple gene therapy approach in AIDS/lymphoma patients.